Dr. Sattentau obtained his Bachelor's degree in microbiology from the University of Bristol and his PhD in viral immunology from the University of London.

 

After some postdoctoral time at University College London, Dr. Sattentau moved in 1989 to the laboratory of Nobel Laureate Richard Axel in New York, and from 1992 to 1998 he was Director of Research at the Centre National de Recherche Scientifique (CNRS) in Marseille, France, where he initiated use of trimeric envelope glycoprotein antigens for antibody-based HIV-1 vaccine design and worked on mechanisms of HIV-1 antibody neutralization. In 1999 he returned to a Senior Lecturer post at Imperial College London, and in 2003 took up a Lectureship at the Sir William Dunn School of Pathology at the University of Oxford. His research interests include antibody-based HIV-1 vaccine antigen design and probing mechanisms underlying adaptive immune activation by post-translationally-modified glycoproteins.

 

In addition to his work with HIV-1, Dr. Sattentau’s experience also includes design of influenza HA-based vaccine antigens to drive elicitation of neutralizing antibodies to highly conserved surfaces, discovery and characterization of novel adjuvants for mucosal and systemic vaccine use, and the development of new models for mucosal vaccine formulation and delivery.

 

Dr. Sattentau’s current interests include work on Covid-19, attempting to understand how different conformational states of the spike protein may influence the elicitation of neutralizing antibodies.

 

He has co-authored more than 200 scientific articles in the field of viral immunology, has more than 15,700 citations and an h-index of 69, is Section Head of Virology for the Faculty of F1000, and is on the Editorial Boards of Trends in Microbiology, The Journal of Virology and the Journal of Translational Medicine.